Dentatorubral pallidoluysian atrophy in South Wales

J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):804-7. doi: 10.1136/jnnp.2007.128074. Epub 2007 Oct 26.

Abstract

Background: Dentatorubral pallidoluysian atrophy (DRPLA) is a rare, autosomal dominant, clinically heterogeneous neurodegenerative disorder characterised clinically by progressive dementia, ataxia, chorea, myoclonic epilepsy and psychiatric disturbance and pathologically by combined degeneration of the dentatorubral and pallidoluysian systems. DRPLA has a marked ethnic predilection, most commonly reported in Japan and thought to be rare in Caucasian populations.

Methods: We describe the clinical and genetic characteristics of 17 patients with DRPLA segregating in four families in South Wales.

Results: There was marked clinical heterogeneity with considerable overlap of symptoms and signs between and within families. The age of onset ranged from 34 to 60 years with an earlier onset associated with myoclonic epilepsy and a later onset associated with a Huntington disease-like presentation. We identified a distinct haplotype within one family not present within the other three families, suggesting that the expansion in at least one family did not arise from an immediate common ancestor. Analysis of repeat length polymorphisms in 306 Welsh control patients identified 14 (4.6%) with repeat lengths in the high-normal range, compared with 0% and 7.4% in previously reported north American Caucasian and Japanese control populations, respectively.

Conclusions: DRPLA may not be as geographically or ethnically restricted as previously thought and the diagnosis should be considered in non-Asian patients presenting with a wide spectrum of neurological disease, especially if there is a dominant family history of dementia or movement disorder. The prevalence of high-normal length alleles may account for the relatively high prevalence of DRPLA in Wales.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Female
  • Founder Effect*
  • Humans
  • Male
  • Middle Aged
  • Myoclonic Epilepsies, Progressive / complications
  • Myoclonic Epilepsies, Progressive / ethnology*
  • Myoclonic Epilepsies, Progressive / genetics*
  • Nerve Tissue Proteins / genetics*
  • Pedigree
  • Polymorphism, Genetic / genetics*
  • Prevalence
  • Wales / epidemiology
  • White People / genetics
  • White People / statistics & numerical data*

Substances

  • Nerve Tissue Proteins
  • atrophin-1